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ABSTRACT
The impact of EGFR-mutant NSCLC precision therapy is limited by acquired 
resistance despite initial excellent response. Classic studies of EGFR-mutant clinical 
resistance to precision therapy were based on tumor rebiopsies late during clinical 
tumor progression on therapy. Here, we characterized a novel non-mutational early 
adaptive drug-escape in EGFR-mutant lung tumor cells only days after therapy 
initiation, that is MET-independent. The drug-escape cell states were analyzed by 
integrated transcriptomic and metabolomics profiling uncovering a central role for 
autocrine TGFβ2 in mediating cellular plasticity through profound cellular adaptive 
Omics reprogramming, with common mechanistic link to prosurvival mitochondrial 
priming. Cells undergoing early adaptive drug escape are in proliferative-metabolic 
quiescent, with enhanced EMT-ness and stem cell signaling, exhibiting global 
bioenergetics suppression including reverse Warburg, and are susceptible to 
glutamine deprivation and TGFβ2 inhibition. Our study further supports a preemptive 
therapeutic targeting of bioenergetics and mitochondrial priming to impact early drug-
escape emergence using EGFR precision inhibitor combined with broad BH3-mimetic 
to interrupt BCL-2/BCL-xL together, but not BCL-2 alone.
INTRODUCTION
EGFR tyrosine kinase inhibitors (TKIs), such as 
erlotinib and gefitinib are approved precision therapies 
for advanced non-small cell lung cancer (NSCLC) 
treatment in patients with drug-sensitizing EGFR-mutant 
tumors [1-3]. As a result of “oncogene-addiction”, EGFR 
TKIs often yields tumor response that can be rapid and 
remarkable [4]. Nonetheless, acquired drug resistance 
invariably develops later in the course of therapy despite 
initial response, leading to ultimate therapeutic failure 
and patient demise even in prior near-complete/complete 
responders. Prior paired rebiopsy studies typically 
emphasized on the late phase of therapy, when clinically 
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evident tumor resistant progression became detectable 
[5-11]. Diverse mechanisms of EGFR-TKI acquired late 
resistance have been described, e.g. T790M-EGFR [8, 
12], MET/HGF activation, HER2 amplification, PIK3CA 
mutation, small cell histologic transformation [5-9] and 
epithelial-mesenchymal transition (EMT) mediated by 
AXL/GAS6 upregulation [10]. Emphasizing on early 
changes of EGFR/MET inhibitors on drug-sensitive 
lung tumor cells [13], we have recently identified and 
characterized the early onset adaptive precision drug 
escape that emerged from the treated drug-sensitive 
parental cell population, after TKI exposure for as short 
as merely 6-9 days. These cells in drug escape exhibited 
~100-fold higher drug-resistance phenotype, and a MET-
independent but enhanced dependence on the intrinsic 
mitochondrial prosurvival signaling cascade [13]. Our 
study also showed that while undergoing drug escape, 
these cells had profoundly inhibited adaptive state of 
proliferation, cell motility and migration (http://cancerres.
aacrjournals.org/content/71/13/4494/ suppl/DC1). 
In the present study, we conducted transcriptome- 
and metabolome-wide profiling to comprehensively 
characterize the cellular state of the early adaptive drug 
escape in EGFR-mutant NSCLC under EGFR-TKI. In 
recent years, cancer metabolism has emerged as a key 
concept capable of providing deeper understanding of 
human malignancies and is now known to integrate 
closely with the oncogenic kinase signaling [14]. Altered 
metabolism is now viewed as a core Hallmark of Cancer 
[15], rather than merely an indirect response to cell 
proliferative and survival signals. We report here that 
transforming growth factor-beta 2 (TGFβ2) autocrine 
upregulation plays a central role in the early adaptive 
omics reprogramming and drug escape in EGFR-mutant 
NSCLC. Our results showed that within the drug escape 
process, there is a link between TGFβ2 and adaptive 
global cellular reprogramming involving bioenergetics-
mitochondrial BCL-2/BCL-xL cascades to promote a 
prosurvival cell state embedded in the proliferative-
metabolic quiescence. Furthermore, we demonstrated now 
that the early adaptive EGFR-TKI drug-resistant cells are 
sensitive to TGFβ2 inhibition and glutamine withdrawal. 
RESULTS
Genome-wide expression profiling of EGFR-
mutant NSCLC early adaptive drug escape 
against EGFR Inhibitor
We have recently reported a MET-independent 
early onset adaptive drug escape among the parental 
drug-sensitive EGFR-mutant lung adenocarcinoma cells 
(HCC827 and PC-9 to erlotinib; H1975 to CL-387,785)
[13]. Here, we extended our studies to perform genome 
expression profiling analysis of the EGFR-mutant NSCLC 
in early adaptive escape against the EGFR inhibitor. 
We used the HCC827 cells (deletion exon 19-EGFR: 
p.Glu746_Ala750del) inhibited by erlotinib (reversible 
EGFR TKI) and H1975 cells (T790M/L858R-EGFR) 
inhibited by CL-387,785 (irreversible EGFR TKI) as in 
vitro preclinical model. Principal component analysis 
(PCA) revealed that the two cell line systems segregated 
well in their gene expression signature profiles (Figure 
1A-1B). These results validated the model systems and 
the treatment conditions adopted in this study. Next, we 
performed BAMarray analysis (incorporating Bayesian 
Analysis of Microarray data) of the gene expression 
microarray datasets (Figure 1C). We found that there were 
dramatic transcriptome expression landscape changes 
during the 9 days of EGFR TKI treatment, resulting in a 
unique and highly homogeneous altered gene expression 
signature pattern in the early onset adaptive drug-
evading cells at day 9 TKI treatment. Importantly, this 
reprogramming of transcriptomic signature is evident in 
both cell line models using HCC827 (Figure 1C, left) and 
H1975 cells (Figure 1C, right) under the corresponding 
TKI treatment with erlotinib and CL-387,785 respectively. 
Common pathway analysis of the significantly 
upregulated and downregulated genes in both cell line 
models was then conducted to identify key signaling 
pathways that are involved in mediating the early adaptive 
drug escape (Figure 1D, table S1, S2). We identified that 
upregulated TGFβ2 potentially played a central role and 
was significantly involved in a multitude of signaling 
pathways in the cells undergoing early adaptive drug 
escape (table S1). Of note, among the top significantly 
upregulated pathway genes within the early adaptive drug 
escaping cells include those regulating cell adhesion, 
cell proliferation, multicellular organismal development, 
extracellular matrix organization, and response to 
hypoxia, among others. On the other hand, pathway 
genes that were significantly downregulated in these cells 
converged into pathways regulating cell cycle (arrest 
and progression), mitosis, cell proliferation, DNA repair, 
nucleosome assembly, chromatin organization and histone 
modification (table S2). Of particular interest, several key 
metabolic enzyme genes involved in glucose metabolism: 
glucose-6-phosphate isomerase (GPI), phosphoglycerate 
kinase 1 (PGK1) and enolase 2 (ENO2), were found to be 
downregulated. 
Autocrine TGFβ2 in the early adaptive EGFR-
TKI drug escape and reprogramming of EMT-
ness, stem cell-like signaling and Warburg 
metabolism
We next sought to investigate the role of autocrine 
TGFβ2 in the emergence of the early adaptive drug 
escape. TGFβ signaling has been well known to be 
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involved in human tumorigenesis although there can 
be complex patterns of its pathway activation as both 
tumor promoter and tumor suppressor, often in a tissue 
context-dependent fashion [16, 17]. TGFβ signaling has 
also been implicated in inducing EMT and cancer stem 
cell-like phenotype [18, 19]. Exogenous TGFβ2 treatment 
(5 ng/ml) in cell culture induced HCC827 cells to adopt 
an EMT-like phenotype (Figure 2A), correlating with 
the erlotinib treatment downregulated E-cadherin and 
induced vimentin expression in cells surviving 9 days of 
TKI (Figure 2A). Using Q-PCR gene expression assay, 
we validated that there was an induction of TGFβ2 mRNA 
expression (2.5-fold) in the HCC827 cells that were 
in escape against erlotinib cytotoxicity (up to 9 days), 
followed by expression reversal after 7 days of drug-
washout (Figure 2B). In addition, we also demonstrated 
that the autocrine TGFβ2 cytokine was adaptively induced 
at day 9 TKI treatment at the protein level, as seen in the 
immunofluorescence study, followed by de-escalation 
after drug-washout (Figure 2C). It is intriguing to note that 
there was a TGFβ2 nuclear translocation from cytoplasmic 
compartment in the early adaptive TKI escaping cells 
evident at 9 days erlotinib inhibition, which was partially 
reversed after 7 days of drug-washout (Figure 2C). 
As reported recently, the early adaptive drug-escaping 
HCC827 cells evading erlotinib inhibition can be observed 
in an in vivo xenograft TKI treatment model [13]. We 
identified that there was upregulation of BCL-2/BCL-xL 
prosurvival signaling and p-STAT3 activation in HCC827 
cells in adaptive escape against erlotinib, primarily 
localizing along the peripheral rind of the tumor xenograft 
as in the TKI evading cells [13]. We now identified that 
Figure 1: Principal component analysis (PCA) of precision therapy of EGFR-mutant drug-sensitive lung adenocarcinoma 
cells. 1A. Segregation of HCC827 (deletion exon 19-EGFR) and H1975 (T790M/L858R-EGFR) cells in the two separate preclinical in 
vitro model systems. Transcriptome-wide profiling of early adaptive drug-escape in EGFR-mutant lung adenocarcinoma was analyzed 
using PCA. HCC827 cells were treated with erlotinib at 1 µM and H1975 cells were treated with CL-387,785 at 1 µM for 9 days followed 
by TKI washout for another 7 days in biologic triplicates. 1B. PCA of the gene expression data from the microarray gene expression 
profiling study as above in 1C. Transcriptomic profiling of early adaptive drug-escape against EGFR-TKI in (a) HCC827 and (b) H1975 
lung adenocarcinoma cells - Clustering heat map analysis. 1D. Pathway analysis from the Affymetrix gene expression microarray studies 
in early adaptive drug-escape against EGFR-TKI in EGFR-mutant lung adenocarcinoma. 
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the HCC827 xenograft under in vivo erlotinib inhibition 
for 4 days resulted in an induction of autocrine TGFβ2 
expression intratumorally in the adaptive TKI-evading 
cells (Figure 2D), associating with a corresponding 
suppression of the proliferative marker Ki-67 expression 
(Figure 2D). Our results support the notion that the early 
adaptive drug escape involves a predominantly cellular 
quiescence state. Moreover, our gene expression clustering 
analysis identified that in both HCC827 cells and H1975 
cells treated under the corresponding EGFR TKI, there 
was an adoptive stem cell signaling gene expression 
reprogramming evident during the early drug escape cell 
state (day 9 under TKI) (Figure 2E).
Immunoblotting analysis further verified at the 
protein levels the modulating effects of erlotinib inhibition 
on expression of various markers of the Warburg effect 
(glucose metabolism genes) and cell cycle gene, identified 
from the gene expression microarray analysis in HCC827 
cells (Figure 3A). Here, we found that the TKI-modulated 
expression of the glycolytic metabolic enzymes GPI, 
PGK1 and ENO2, and the cell cycle progression regulator 
TIMELESS paralleled the expression pattern as observed 
in the transcriptomic analysis. All these markers were 
found consistently downregulated in the early adaptive 
drug-evading cells, but readily reversible upon TKI-
washout (Figure 3A-a, 3A-b). Next, we asked if direct 
Figure 2: Autocrine TGFβ2 upregulation in lung adenocarcinoma early adaptive drug-escape correlated with EMT 
and stem cell signaling reprogramming. 2A. HCC827 cells persisting under 9 days of erlotinib treatment displayed progressively 
downregulated expression of E-cadherin and remarkably increased expression of vimentin at day 9. Bright field microscopic images (right) 
showed HCC827 cells treated with exogenous TGFβ2 (5 ng/mL) for 9 days. 2B. Q-PCR results verified that the TGFβ2 gene expression 
was upregulated in HCC827 lung adenocarcinoma cells in adaptive escape against erlotinib. HCC827 cells were treated in culture without 
or with erlotinib for the indicated time durations, and TGFβ2 expression was elevated in both 8 hr (1.5 fold) and 9 days (~2.5 fold) cell 
groups when compared with control cells (DMSO treated) * p < 0.01. 2C. Immunofluorescence staining of TGFβ2 expression in HCC827 
cells treated with erlotinib. Immunocytochemistry shows the TGFβ2 protein expression in cells treated with erlotinib at 3 different time 
points (8Hr, 9D and 9D+7D washout). DAPI nuclear staining (nuclear stain) is shown in the upper panel, TGFβ2 protein (green) staining 
alone is shown in the middle panel and both are merged and shown in the bottom panel. Scale bar - 10 µm. 2D. In vivo murine xenograft 
model of early adaptive drug-escape against erlotinib in HCC827 EGFR-mutant lung adenocarcinoma revealed upregulated TGFβ2 and 
depressed Ki-67 expression. IHC analysis of the post-treatment xenograft tumors using primary antibodies against human TGFβ2 and Ki-
67 were performed and shown here (representative images). 2E. Heat map analysis of stem cell signaling genes expression in EGFR-mutant 
NSCLC. 
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TGFβ2 effects on HCC827 cells would recapitulate that 
observed under erlotinib inhibition as above. We found 
that exogenous TGFβ2 was sufficient to inhibit, in a 
concentration dependent fashion, the expression levels 
of the key glycolytic metabolic enzymes involved in the 
“Warburg effect”, GPI, PGK1 and ENO2 (Figure 3B-a). 
Importantly, we also validated that exogenous TGFβ2 is 
sufficient to induce the intrinsic mitochondrial prosurvival 
priming with enhanced expression of the markers BCL-2 
and BCL-xL in the drug-evading HCC827 cells (Figure 
3B-b). Similar results were obtained and validated in 
another EGFR-mutant lung adenocarcinoma cell line PC-9 
(Figure 3B-c). Finally, we extended our gene expression 
signature analysis into other well-recognized Warburg 
metabolism regulatory genes PKM2, LDHA, ENO1, TPI1 
and GAPDH, and found that they were all adaptively 
downregulated in expression within the EGFR-mutant 
NSCLC cells under EGFR-TKI drug escape (Figure 3C). 
Finally, to directly assess the functional significance of 
TGFβ2 in the emergence of early adaptive resistant cells, 
we performed RNAi-silencing of TGFβ2 in HCC827 
cells subjected to precision treatment with erlotinib for 
9 days (Figure 3D-a). Upon TGFβ2 RNAi knockdown, 
there was a significant impact leading to downregulation 
of both BCL-2 and BCL-xL expression, while there was 
no difference in the expression of BIM (Figure 3D-b & 
Figure 3: Downregulation of glycolytic regulatory enzymes expression through TGFβ2 signaling to promote pro-
survival mitochondrial-priming. 3A. Induction of autocrine TGFβ2 cytokine expression in HCC827 cells persisted after 9 days of 
erlotinib treatment undergoing adaptive drug-escape, correlated with downregulated expression of the key glucose metabolism regulatory 
enzymes GPI, PGK1 and ENO2, as well as the cell cycle progression regulator TIMELESS. (a): HCC827 cells were treated without (0 hr) or 
with erlotinib for 8 hr, 9 days, and 9 days of TKI followed by 7 days of drug washout. Actin (bottom panel) was included as loading control. 
(b): Gene expression heat map signature showing adaptive suppression in gene expression of glucose metabolism regulatory Warburg genes 
GPI, PGK1 and ENO2 in HCC827 cells (upper panel) treated with erlotinib and H1975 cells (lower panel) treated with CL-387,785. TKI 
treatment conditions: a, 0 hr (untreated control); b, 8 hr; c, 9 days and d, 9 days of TKI followed by 7 days of drug washout. 3B. Immunoblot 
analysis of the effect of TGFβ2 on HCC827 and PC-9 cells in the expression levels of the glucose metabolism regulatory enzymes: GPI, 
PGK1, ENO2, and the mitochondrial prosurvival marker BCL-2/BCL-xL. (a) HCC827 cells were treated with exogenous TGFβ2 (5 
ng/ml) for 9 days, at increasing concentration of the cytokine as indicated for immunoblotting. (b & c) HCC827 and PC-9 cells under 
similar treatment conditions as above were subjected to immunoblotting. 3C. Gene expression heat map signature of suppressed Warburg 
glycolytic enzyme genes in early adaptive EGFR-mutant NSCLC cells under targeted EGFR-TKI treatment. HCC827 cells treated with 
erlotinib (upper panel) and H1975 cells treated with CL-387,785 (lower panel). PKM2, pyruvate kinase M2; LDHA, lactate dehydrogenase 
A; ENO1, enolase 1; TPI1, triosephosphate isomerase 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. TKI treatment conditions: 
a, 0 hr (untreated control); b, 8 hr; c, 9 days and d, 9 days of TKI followed by 7 days of drug washout. 3D. (a) SiRNA-specific silencing 
of TGFβ2 (3 days) in erlotinib-treated HCC827 cells for 9 days compared with the untreated, 9-day treated erlotinib and the mock control-
treated HCC827 cells. (b & c) siRNA knockdown of TGFβ2 shows a significant reduction in mRNA expression of TGFb2, BCL-2, and 
BCL-xL. BIM showed no significant difference in expression upon siRNA silencing of TGFβ2.
Oncotarget82018www.impactjournals.com/oncotarget
3D-c). 
Remarkable global metabolome reprogramming 
of key bioenergetics pathways in HCC827 lung 
adenocarcinoma cells during early adaptive drug 
escape
We further adopted a mass-spectrometry based 
global metabolomics platform to quantitatively 
profile the expression of metabolites in HCC827 cells 
under erlotinib treatment. Here, we demonstrated 
that there was a dramatic metabolome-wide adaptive 
reprogramming of key bioenergetics pathways in the 
HCC827 cells undergoing drug escape against erlotinib. 
The present dataset comprises a total 356 compounds 
of known identity (named biochemicals). Following 
log transformation, normalization to Bradford protein 
concentration and imputation with minimum observed 
values for each compound, Welch’s two-sample t-test was 
used to identify biochemicals that differed significantly 
between experimental groups. A summary of the numbers 
of biochemicals that achieved statistical significance 
(p≤0.05), as well as those approaching significance (0.05 
< p < 0.10), is shown in tables S3. 
Glucose metabolism and glutaminolysis 
reprogramming (Figure 4A). 
Significant alterations were observed in glycolytic 
and TCA cycle intermediates and glutaminolysis within 
the early onset drug resistant tumor cells. In cells treated 
with erlotinib, the glucose flux through the glycolytic and 
tricarboxylic acid (TCA) pathways and glutaminolysis 
was apparently reduced after the TKI treatment for 9 days 
and 9 days TKI + 7 days drug-washout. Treatment with 
erlotinib in 8 hr did not significantly affect the glycolytic 
intermediates whereas an increase was observed in levels 
of glutamine, glutamate and the TCA cycle intermediates 
such as citrate, succinate and its carnitine derivate succinyl 
carnitine, fumarate and malate as compared to vehicle-
treated controls. This increase is suggestive of increased 
TCA cycle flux and is consistent with the observed 
increase in glucose utilization. A large effect in 9 days of 
erlotinib treatment was observed as there were significant 
Figure 4A: Glucose metabolism, TCA cycle and glutaminolysis reprogramming. 4B. Erlotinib-treated HCC827 cells were treated with 
and without glutamine for 9 days followed by three days of no treatment. 4C. Relative number of viable early adaptive resistant cells 
without glutamine was significantly reduced compared with the cells treated with glutamine.
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elevations in glucose, fructose, several glycolytic 
intermediates, and lactate. Furthermore, the survivor cells 
in drug-escape exhibited significantly reduced levels of 
succinate, fumarate and glutamate, despite significant 
increases in glutamine and glutamate, suggestive of 
reduced TCA cycle activity and decreased glutaminolysis. 
These changes are consistent with a large reduction in 
glucose utilization after 9 days of erlotinib inhibition, 
supporting the notion that the early adaptive drug escape 
cells adopt a cellular-metabolic quiescence-like state [13]. 
After an additional 7 days drug-washout period following 
9 days of erlotinib treatment, glucose utilization was 
resumed and may be slightly greater than that observed 
in vehicle-treated control while the TCA cycle activity 
was also reversed and became similar to that observed in 
untreated control cells. We next asked if the adaptive drug-
resistant tumor cells could be newly addicted to glutamine. 
To test this, HCC827 cells were cultured in the presence 
or absence of glutamine, under EGFR TKI treatment 
with erlotinib for 9 days followed by 3 washout days. 
Glutamine-withdrawal led to significantly less viable early 
adaptive erlotinib-resistant cells suggesting that the cells 
adopted a degree of glutamine-addiction during the drug-
induced metabolic reprogramming (Figure 4B and 4C). 
Branched-chain amino acid catabolism reprogramming 
(Figure 5, left; and Figure S2)
Degradation products formed from the catabolism of 
the branched-chain amino acids (BCAA) valine, isoleucine 
and leucine are used for anaplerotic contribution to the 
TCA cycle. Despite minimal changes in levels of TCA 
cycle intermediates; there was a reduction in BCAA 
carnitine conjugates after 8 hours of erlotinib treatment. 
However, 9 days of erlotinib significantly increased valine, 
isoleucine, and leucine and their carnitine derivatives, 
suggestive of reduced entry into the TCA cycle which is 
consistent with reduced glucose utilization and TCA cycle 
intermediates in cells evading erlotinib therapy. After the 
7 days erlotinib withdrawal period, levels of BCAAs were 
significantly reduced and the carnitine conjugates remain 
slightly elevated, suggestive of reduced oxidation of these 
amino acids for energy and potential increased utilization 
for protein synthesis.
Lipid metabolism reprogramming (Figure 5, right, 
table S4)
One of the most striking and consistent changes 
observed was a significant increase in many essential, 
medium-chain and long-chain fatty acids found in cells 
that persisted after 9 days of erlotinib treatment. Significant 
elevations in the fatty acid synthesis precursors - citrate, 
acetyl CoA and its carnitine derivative acetylcarnitine, are 
Figure 5: Branched-chain amino acid catabolism, and Lipid metabolism reprogramming in early adaptive drug-
resistant HCC827 EGFR-mutant cells under erlotinib inhibition. 
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suggestive of a blockage in fatty acid synthesis; therefore, 
increased fatty acid synthesis reflects increased uptake 
and/or decreased synthesis of membrane phospholipids 
as several precursors in the biosynthetic pathway such 
as choline, ethanolamine and phosphoethanolamine were 
significantly elevated. Furthermore, cell membranes 
are highly enriched in sphingolipids and the significant 
reduction in palmitoyl sphingomyelin and stearoyl 
sphingoymyelin are supportive of the notion of reduced 
membrane synthesis with 9 day treatment of erlotinib. 
This is also consistent with a proliferative quiescence-state 
observed at 9 day treatment of erlotinib [13]. Conversely, 
the opposite findings of reduced levels of many free 
fatty acids and decreased precursors of membrane lipid 
synthesis with 9 days erlotinib + 7 days drug-washout 
are consistent with the notion of an adaptive increased 
proliferation and growth as a result of the removal of 
therapeutic stress.
Figure 6: Early adaptive transcriptomic-metabolomic cellular reprogramming under EGFR-TKI precision therapy 
to promote resistant drug-escape. 6A, The schematic diagram highlights the central role of autocrine TGFβ2 in EGFR oncogene-
addicted NSCLC. 6B, Cells were then treated with erlotinib (1 µM) for up to 9 days, with intermittent inhibitor replenishment every 3 
days. After that, cells were further treated for 3 additional days using (a) diluent alone, (b) erlotinib alone, ABT-199 without (c) or with (f) 
continuing erlotinib, ABT-263 without (d) or with (g) continuing erlotinib, obatoclax without (e) or with (h) continuing erlotinib. HCC827 
cells were also treated concurrent at the beginning of the experiment using erlotinib (1 µM) plus the respective BH3 mimetics (2 µM) as 
above (i: ABT-199, j: ABT-263, and k: obatoclax). 6C, Spectrometric quantification of the different groups including the untreated (A), 
treated with erlotinib (B: 12 days 1 µM Erlotinib), treated with erlotinib and ABT-263 (C: 12 days 1 µM Erlotinib + 3 days 2 µM ABT-263; 
D: 9 days 1 µM Erlotinib + 3 days 2 µM ABT-263; E: 12 days 1 µM Erlotinib + 12 days 2 µM ABT263), treated with erlotinib and ABT-199 
(F: 12 days 1 µM Erlotinib + 3 days 2 µM ABT-199; G: 9 days 1 µM Erlotinib + 3 days 2 µM ABT-199; H: 12 days 1 µM Erlotinib + 12 
days 2 µM ABT-199) and treated with Obatoclax (I: 12 days 1 µM Erlotinib + 3 days 2 µM Obatoclax; J: 9 days 1 µM Erlotinib + 3 days 
2 µM Obatoclax; K: 12 days 1 µM Erlotinib + 12 days 2 µM Obatoclax). (ns - not significant; ** p < 0.002; *** p < 0.001).
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Inflammation and endocannabinoids reprogramming 
(Figure S3)
A large increase in arachidonate (20:4n6) 
and two associated eicosanoids, 13,14-dihydro-15-
keto-prostaglandin E2 and 13,14-dihydro-15-keto-
prostaglandin E2, were observed exclusively with 9 days 
of erlotinib treatment in HCC827 cells. Interestingly, 
short-term increases in oleic ethanolamide, palmitoyl 
ethanolamide, N-stearoyl taurine, N-palmitoyl taurine, 
and oleoyltaurine were observed with 8 h of erlotinib 
treatment, followed by significant reductions in all 
endocannabinoids except palmitoyl ethanolamide with 9 
day of TKI therapy. In addition to effects on tumor cell 
proliferation and apoptosis, N-acyl taurines are known to 
activate the transient receptor potential (TRP) family of 
calcium channels. One member of this family, TRPV4, 
is involved in regulation of osmotic pressure, and several 
major osmolytes including glycerophosphorylcholine 
(GPC), myo-inositol, and taurine were significantly 
elevated in cells evading erlotinib treatment after 9 days. 
These findings are reflective of a cell state in an attempt at 
protection against hypertonicity and osmotic stress.
Neuropeptide signature (Figure S4)
Synthesis of N-acetylaspartate (NAA) and N-acetyl-
aspartyl-glutamate (NAAG) was found selectively 
increased only after 9 days of treatment with erlotinib. 
Serotonin (5HT) production was significantly greater in 
cells treated with erlotinib for 8h and 9 days compared 
to vehicle-treated controls, but after the 7 days washout 
period, serotonin levels were similar in both treatment 
groups. 
Methionine metabolism and oxidative stress (Figure 
S5)
Depletion of the tripeptide glutathione and 
associated increases in oxidative stress are a hallmark 
of many cancers. Indeed, in HCC827 cells treated with 
vehicle and erlotinib, there was a reduction in both 
oxidized glutathione (GSSG) and reduced glutathione 
(GSH) over time as compared to untreated control. 
Interestingly, there was a large increase in levels of 
cysteine, the rate-limiting biochemical for synthesis of 
glutathione, after 9 days and 9 days plus 7 days washout 
of vehicle treatment, suggestive of a “blockage” in 
glutathione synthesis. Nine days of erlotinib treatment 
induced a massive depletion of cysteine with concurrent 
increases in methionine, taurine, and ophthalmate, 
suggestive of a shunting of cysteine toward alternative 
pathways other than glutathione synthesis. As mentioned 
previously, increased taurine levels may be related to 
endocannabinoid synthesis and/or osmoregulation, and 
increased ophthalmate, a glutathione-like biochemical 
synthesized by the same enzymes as glutathione, indicates 
that the reduction in cysteine was the limiting factor for 
glutathione synthesis after 9 days of erlotinib therapy. 
Similarly, depletion of cysteine induced by 9 days of 
erlotinib therapy was likely responsible for the significant 
reduction in the oxidative stress marker cysteine-
glutathione disulfide, as opposed to an actual improvement 
in oxidative environment.
Arginine metabolism and polyamines (Figure S6)
Treatment with erlotinib significantly affected 
arginine metabolism after 9 days of therapy, as conversion 
of arginine to citrulline by inducible nitric oxide synthase 
(iNOS) may be reduced due to a significant elevation in 
dimethylarginine (ADMA/SDMA), a potent endogenous 
inhibitor of iNOS activity. Increased dimethylarginine 
may be indicative of elevated oxidative stress, as levels 
of carnosine, a dipeptide derivative that functions as an 
antioxidant, were selectively elevated at this time point as 
well. In addition, alternative pathways for metabolism of 
arginine were affected by 9 days of erlotinib treatment as 
creatine and creatinine were elevated, ECM remodeling 
was altered as evidenced by increased proline and pro-
hydroxy-pro, and production of the polyamines spermidine 
and spermine was significantly increased. 
TGFβ2-BCL-2/BCL-xL linked mitochondrial 
metabolically-regulated prosurvival cascade in 
early adaptive drug escape can be therapeutically 
targeted
Using BH3 mimetics [20] with differential 
mitochondrial inhibitory activities, i.e. ABT-263 [21], 
ABT-199 [22, 23], and obatoclax [24, 25], we further 
tested the hypothesis that the EGFR TKI induced, TGFβ2-
mediated mitochondrial prosurvival priming can be 
therapeutically targeted to prevent or eradicate the early 
adaptive drug escape in EGFR-mutant NSCLC. In an in 
vitro cell survival assay in HCC827 cells under treatment 
with (i) erlotinib alone, and (ii) erlotinib plus BH3 mimetic 
- either ABT-263 (dual BCL-2/BCL-xL potent), ABT-199 
(BCL-2 > > BCL-xL potent), or obatoclax (pan-BCL-2 
family potent) inhibitor (Figure 6). The BH3 mimetic was 
added either at day 0 concurrently with erlotinib or at day 9 
after erlotinib induced mitochondrial priming emergence, 
with or without ongoing concurrent erlotinib for 3 
additional days. Our results show that it is more efficacious 
to adopt a concurrent approach to combine EGFR TKI 
erlotinib with a dual BCL-2/BCL-xL BH3 mimetic with 
ABT-263 from the start of therapy to preemptively prevent 
the emergence of early adaptive drug-escape cells against 
erlotinib (Figure 6B: g, h, j, k). Of note, ABT-199 with 
highly specific potent activities against BCL-2 only but 
not BCL-xL, did not show significant efficacy here (Figure 
6B: c, f, i & Figure 6C), further validating our previous 
observation in RNAi knockdown studies that BCL-xL is 
necessary therapeutic partner with BCL-2 to effectively 
inhibit the early adaptive erlotinib resistant HCC827 
cells [13]. Interestingly, the pan-BCL-2 family inhibitor 
obatoclax yielded a superior efficacy in both preventing 
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the emergence of early adaptive drug escape as well as 
eradication of the mitochondrially primed drug-persisting 
cells emerged after 9 days of prior erlotinib inhibition. 
DISCUSSION
The challenge of clinical tumor resistance remains 
a major bottleneck to meaningfully impact long term 
survival outcome of precision therapy in EGFR-mutant 
lung cancer. We and others have recently identified a novel 
paradigm of early emergence of adaptive subpopulation 
of EGFR-mutant lung cancer cells in escape against 
the corresponding targeted inhibitor from the parental 
drug-sensitive cell population within a very “early” 
time-window only days after therapy initiation [13, 26]. 
These early adaptive drug evading survivors likely serve 
as the founder population as minimal residual disease 
under therapeutic pressure, which ultimately evolve into 
clinically detectable resistant progressive disease on 
therapy late in the future [13, 26, 27]. 
The early adaptive drug-evading HCC827 cells 
also showed downregulated E-cadherin and upregulated 
expression of EMT inducer protein marker vimentin, 
besides TGFβ2. The cell state molecular switch from 
epithelial to mesenchymal phenotype has been associated 
with activation of signaling and transcription factors 
primarily involving TGFβ signaling. EMT induction 
has been demonstrated to play key role in late clinical 
acquired EGFR inhibitor resistance [10] and as supported 
by our study results, may indeed have initiated very early 
in drug escape process within the continuum of clinical 
drug resistance evolution. Altered cellular metabolism 
is now known to often exist in human cancers [28, 
29], playing a direct tumorigenic role in the process. 
Otto Warburg first observed the phenomenon in the 
1920s, now known as the “Warburg effect” or “aerobic 
glycolysis”. Normal cells depend predominantly on 
mitochondrial oxidative phosphorylation to generate 
ATP and energy from glucose. In contrast, cancer cells 
can rewire their metabolic programs in preference to 
metabolize glucose in a larger part by glycolysis, resulting 
in increased glucose consumption and lactate production 
even in the presence of ample oxygen [14, 30, 31]. Of 
particular interest, our current study results notably 
identified a novel adaptive metabolomic reprogramming 
under molecularly targeted therapeutics stress resulting 
in globally suppressed cellular metabolism including 
glycolytic pathway, TCA cycle pathway, branched chain 
amino acids metabolism, lipid biogenesis, and enhanced 
inflammatory metabolism, evidently in an overall effort to 
promote tumor cells survival and therapeutic escape. The 
practical implication is that these adaptive EGFR-mutant 
lung cancer cells that survive erlotinib in escape would 
also evade detection by clinical 18FDG-PET scanning due 
to their suppressed glucose metabolism, forming therefore 
the basis of radiographic complete response (CR) or near-
CR despite the presence of minimal residual tumor disease 
in therapeutic escape. These quiescent minimal residual 
molecular drug-resistant tumor cells in drug-escape could 
ultimately evolve with time into full proliferative resistant 
progressive disease late in the future. 
Our study findings not only established the relevance 
of autocrine TGFβ2 in early adaptive EGFR-TKI drug-
escape in EGFR-mutant NSCLC, but also highlight 
for the first time, to our best knowledge, that TGFβ2 
signaling links with the mitochondrial BCL-2/BCL-xL 
prosurvival cascade in the context of a profound cellular 
metabolome reprogramming. We recently presented both 
in vitro and in vivo evidence [13] to support the notion 
that the druggable BCL-2-family signaling in the intrinsic 
mitochondrial programmed-cell death pathway may 
represent a central mechanism in EGFR-TKI-induced 
mitochondrial priming [32, 33] to achieve new prosurvival 
dependence in promoting and sustaining early adaptive 
drug escape against the TKI [13, 34]. We also presented 
the first in vivo proof-of-concept evidence to support the 
efficacy of combination BCL-2/BCL-xL BH3 mimetic 
with EGFR TKI in circumventing early adaptive drug 
resistance and thus resulting in durable tumor response in 
EGFR-mutant NSCLC precision therapy [13]. Here, we 
show that through shRNA knockdown studies, TGFβ2 
directly mediates the survival of the adaptive EGFR-
TKI drug-escaping tumor cells, and that it also directly 
regulates the mitochondrial BCL-2/BCL-xL expression 
downstream, but not BIM. Moreover, our omics profiling 
study revealed profound genome- and metabolome-wide 
cellular reprogramming within EGFR-mutant NSCLC 
cells undergoing early drug-escape, mediated by TGFβ2 
autocrine signaling. Importantly, we further demonstrated 
that such large scale omics landscape alteration represents 
a highly reversible adaptation to the therapeutic stress, 
hence highlighting the critical importance of gene 
expression changes and metabolic regulation in precision 
therapy tumor resistance, a perspective that was not well 
appreciated in the past. Our current study also provided 
evidence to suggest that BCL-xL is a key therapeutic 
target, rather than merely BCL-2 alone, in the process 
of early adaptive EGFR-TKI drug escape emergence. 
Hence, it is crucial to adopt at least dual BCL-2/BCL-
xL BH3-mimetic (ABT-263), or even pan-BCL-2 family 
BH3-mimetic (obatoclax) inhibitor [20, 24, 25, 35-37], 
in order to effectively prevent or eradicate early adaptive 
mitochondrially-primed tumor escape. Moreover, the 
early adaptive drug-resistant cells were also found to 
be vulnerable to glutamine deprivation, suggesting that 
they were relatively glutamine-addictive. Glutamine is 
known to serve as a crucial nitrogen donor for nucleotide 
synthesis. MYC has also been shown to play as a key 
promotional factor to the metabolic process of converting 
glutamine into glutamic acid, which ultimately would be 
converted to lactic acid towards the end of the metabolism. 
According to the Warburg effect, the cancer cell undergo 
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oncogenic activation of glucose uptake and metabolism, 
often induced by constitutively activated PI3K signal 
path. This Warburg’s metabolism leads to resultant 
cellular secretion of excess glycolytic metabolites in the 
form of lactic acid. This apparent inefficient metabolism 
of glucose is observed in parallel in some human tumors 
implicated to display “glutamine-addiction”, and that 
the cellular survival is dependent on the presence of 
exogenous glutamine [38]. Previous reports suggest cell 
death induced by glutamine-depletion is mediated through 
the intrinsic mitochondrial apoptotic pathway, as it could 
be rescued by BCL-2/BCL-xL overexpression, or a 
dominant-negative caspase-9 [39].
To this end, it is also of interest to identify 
the autocrine TGFβ2 signaling as the key cellular 
reprogramming mediator within the early adaptive drug 
escaping cells. TGFβ signaling has been shown to play 
important roles in human tumorigenesis with relatively 
complex tissue-specific and stromal context-specific 
signaling effects [40]. Its activation can be highly 
contextual in nature, both pivotal in early tumorigenesis 
process as “tumor suppressor” and in late stages of 
tumorigenesis and progression as “tumor promoter” 
[41]. Furthermore, the role of TGFβ signaling has been 
much better understood as a stromal influence in cancer 
development [42]. TGFβ signaling has been implicated as 
a link to increased ERK signaling and TKI resistance in 
PC-9 NSCLC cells through loss of MED12 [43-45]. Here, 
our studies suggest that specifically TGFβ2 signaling 
activation is autocrine in nature, and mimics a “tumor 
suppressor” effect in short-term perspective to suppress 
tumor cell metabolism, proliferation, and motility in 
the early cellular adaptive drug escape against erlotinib, 
resulting in a long term overall tumor survival promotion 
that would ascertain the ultimate persistence, proliferative 
resistance and survival of the NSCLC cells throughout the 
therapeutic stress. 
In conclusion, our study revealed a profound 
transcriptomic-metabolomic cellular reprogramming 
during the early-onset drug escape of EGFR-mutant 
NSCLC cells against precision therapy, with resultant 
significant mitochondrial prosurvival priming. This 
was correlated with an autocrine TGFβ2 upregulation, 
increased EMT-ness and cancer stemness, arrested cell 
cycle and cytoskeletal function, and remarkable adaptive 
transcriptome-metabolome-bioenergetics alterations 
(Figure 6). It would be attractive to further validate these 
findings in prospective serial rebiopsy study in EGFR-
mutant patients under EGFR-TKI therapy, including the 
early time-window in the midst of tumor response (1st 
week to 1-2 months post-therapy), using comprehensive 
transcriptomic profiling analysis [43]. The key metabolic 
deregulation involved global reduction in glucose 
metabolism, TCA cycle activity, glutaminolysis, oxidation 
of branched-chain amino acids, and reduced synthesis of 
fatty acids and membrane lipid components. This overall 
reduction in energy metabolism was accompanied by 
significant increases in several cofactors, including ADP, 
ATP, NAD+, NADH, NADP+, and coenzyme A, likely 
due to reduced energy demands and utilization. Finally, 
we show that the early adaptive drug-resistant EGFR-
mutant tumor cells under reprogrammed transcriptomic/
metabolomics profiles can be secondarily targetable 
in principle, and are vulnerable to TGFβ2 inhibition, 
and glutamine-depletion. Last, we also provide further 
evidence to the efficacy of combined EGFR-TKI and 
BCL-xL-targeting BH3 mimetic [46] co-inhibitory 
strategy to dampen the emergence of early adaptive drug 
escape in EGFR-mutant NSCLC precision therapy. Our 
results further nominated the prosurvival mitochondrial 
marker BCL-xL as an important and necessary co-target 
in addition to BCL-2 itself, to achieve optimal therapeutic 
efficacy to eradicate the emergence of adaptive EGFR-
TKI evasion. Hence, it would now be feasible to derive 
rationally designed co-inhibitory strategy to prevent 
or overcome early adaptive drug-resistance emergence 
targeting the TGFβ2-mediated mitochondrial bioenergetics 
reprogrammed prosurvival attractive paths at the nodal 
points of BCL-xL and glutamine metabolism. Further 
validation studies to test these secondary combination 
strategies to combat EGFR-TKI drug resistance emergence 
promise to further optimize cancer precision therapy by 
enhancing the duration of therapy response and impacting 
long term clinical outcome. 
MATERIALS AND METHODS
Chemicals, cell culture, immunoblotting and 
immunofluorescence
EGFR inhibitor (reversible) erlotinib was prepared 
as previously described [47, 48]. EGFR inhibitor 
(irreversible) CL-387,785 was obtained from EMD-
Calbiochem (Cambridge, MA). The BH3 mimetics, ABT-
263 (navitoclax), ABT-199 and obatoclax were purchased 
from Selleck, Inc. (Houston, TX). ABT-263 is a potent 
inhibitor of BCL-xL, BCL-2 and BCL-w with Ki of ≤ 0.5 
nM, ≤1 nM and ≤1 nM, but binds more weakly to MCL-1 
and A1. ABT-199 (GDC-0199) is a potent BCL-2-selective 
inhibitor with Ki of < 0.01 nM, > 4800-fold more selective 
versus BCL-xL and BCL-w, and no activity to MCL-1. 
Obatoclax (GX15-070) is a pan-BCL-2 family antagonist 
with Ki of 0.22 μM.
Lung cancer cell lines were obtained directly 
from American Type Culture Collection (ATCC) and 
grown under standard cell culture conditions. Cell lines 
characterization and authentication were performed by 
the ATCC Molecular Authentication Center, using COI 
for interspecies identification and STR analysis (DNA 
fingerprinting) for intraspecies identification. SDS-PAGE 
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and Western blotting were performed as previously 
described [48, 49]. The primary antibodies used are as 
follows: BCL-2, BCL-xL, (both from Zymed), TGFβ2 
(ab66045, Abcam, Cambridge, MA), GPI (H-300, SC-
33777, Santa Cruz), PGK1 (PA5-13973, Thermo Fischer 
Scientific, Inc., Waltham, MA), ENO2 (LS-CC88776, 
LifeSpan BioSciences, Albuquerque, NM), TIMELESS 
(3709-1, Epitomics, Burlingame, CA) and actin (I-19, 
Santa Cruz). 
For cell survival assays in the studies of cells under 
9 days of pretreatment under targeted inhibitors, the 
indicated inhibitors in the culture media were replenished 
at least every 2-3 days prior to cell harvesting at the end 
of the inhibitory culture for subsequent cellular assays. 
Crystal violet cell survival staining assay was performed 
as previously described [13]. For immunofluorescence 
staining, HCC827 cells of different groups of 0hr, 8hr, 
D9 and D9+7 treated with erlotinib in Nunc chamber 
slides were fixed in 4% formaldehyde followed by 
permeabilization with 0.2% Tr-X 100 for an hour at 4°C. 
The cells were then washed with PBS three times and 
blocked for an hour in 5% normal donkey serum for 1 
hr at room temperature. The cells were then incubated 
with TGFβ2 primary antibody overnight at 4°C, washed 
with PBS three times and then incubated with AF488 
anti-rabbit secondary antibody for an hour at room 
temperature. Cells were then washed three times with 
PBS. The slides were then observed and recorded under 
fluorescence microscopy.
Transcriptomic profiling of gene expression: 
affymetrix microarray analysis
Total RNA samples were extracted from triplicate 
cell culture samples from 0hr (Untreated control), 8hr, 
Day 9 and Day 9+7 (9 days of TKI followed by 7 days 
of drug wash-out) for the two NSCLC cell lines namely, 
HCC827 and H1975, treated with erlotinib and CL-
387,785 respectively, according to standard procedures. 
The samples were then submitted to the Gene Expression 
and Genotyping Facility of the Case Comprehensive 
Cancer Center for transcriptomic profiling. Sample 
aliquots (150 ng) were prepared for microarray using 
Ambion’s WT expression kit (Cat# 4411974) according 
to the manufacturer’s instructions. Total RNA samples 
were extracted from triplicate cell culture samples from 
0hr (Untreated control), 8hr, Day 9 and Day 9+7 (9 days 
of TKI followed by 7 days of drug wash-out) for the two 
NSCLC cell lines namely, HCC827 and H1975, treated 
with erlotinib and CL-387,785 respectively, according to 
standard procedures. The samples were then submitted to 
the Gene Expression and Genotyping Facility of the Case 
Comprehensive Cancer Center for transcriptomic profiling 
and analysis (details see Supplemental Methods). 
Quantitative real-time-polymerase chain reaction 
(Q-RT-PCR)
Gene expression of TGFβ2 was verified by 
quantitative real-time polymerase chain reaction (Q-RT-
PCR). Total RNA extractions were performed with an 
RNeasy Plus Mini kit (Qiagen). cDNA were synthesized 
from RNA samples with an iScript cDNA synthesis kit 
(BIO-RAD). After cDNA synthesis, PCR reactions were 
setup with an iQ SYBR Green Supermix kit (BIO-RAD). 
Relative quantification was done on Fast Real-Time PCR 
system (ABI 7500). Using the comparative threshold 
cycles (CT) method, the quantification normalized 
to untreated cells were performed. Experiments were 
performed in triplicates. 
Exogenous TGFβ2 treatment of HCC827 cells
HCC827 and PC-9 cells were treated with 
exogenous TGFβ2 in different concentrations of 1.5 ng/ 
mL, 2.5 ng/ mL and 5 ng/ mL for 9 days. Cell lysates were 
prepared from the different concentrations of TGFβ2 
treatment and immunoblotting was performed using these 
lysates probed with different anti-apoptotic and metabolic 
primary antibodies. The cells were also observed under the 
microscope at the end of the treatment. 
Preparation and transfection of siRNAs targeting 
TGFβ2
In this study, siRNAs targeting TGFβ2 (Ruibo, 
Guangzhou, China) were employed in HCC827 cells for 
knockdown experiments. The sequences of each siRNA 
pair were as follows: CGGAGGTGATTTCCATCTA, 
CGACAGCAAAGTTGTGAAA, 
CTATAAAGTCCACTAGGAA. siRNAs were transfected 
into 90-100% confluent HCC827 cells at the final 
concentration of 10 nM using standard methods. Two to 
three days after transfection, the efficacy of knockdown 
was assessed by QPCR. 
Glutamine deprivation of HCC827 cells
HCC827 were treated with and without glutamine, 
which were treated with erlotinib for 9 days followed by 
3 days of drug-washout. The cells were then fixed and 
assayed under the microscope at the end of the treatment, 
with crystal violet cell survival staining. The stained 
viable cells were quantified and plotted for the comparison 
between glutamine-treated and glutamine-withdrawn 
groups. 
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Metabolomics profiling
Global biochemical profiling was performed using 
HCC827 cell samples, the groups being untreated cells at 
time 0 and cells treated with erlotinib (1 µM) or DMSO 
(dimethyl sulfoxide) vehicle at 3 time points of 8 hr, Day 9 
and Day 9+7 (9 days erlotinib/DMSO, followed by 7 days 
washout), with 5 replicate in each treatment group. All 35 
samples were extracted using the automated MicroLab 
Star® system from Hamilton Company (Metabolon Inc., 
Durham, NC). Recovery standards were added before the 
extraction process for QC purposes. Sample preparation 
was performed using a proprietary series of organic and 
aqueous extractions that allow maximum recovery of 
small molecules. Details of the methods of metabolomics 
profiling and analysis is described in the Supplemental 
Methods and Materials. 
In vivo xenograft model of HCC827 NSCLC
HCC827 and their corresponding murine xenograft 
models without or with erlotinib treatment for 4 days (n 
= 6/group), were established as previously described, 
according to institution approved protocols and guidelines 
[13, 49]. The studies were conducted in accordance 
with the NIH Guide for the Care and Use of Laboratory 
Animals. Hematoxylin & eosin (H&E) staining and 
immunohistochemical (IHC) analysis of the tumor 
xenograft was performed in the Image Core, Cleveland 
Clinic, using anti-human TGFβ2, and anti-human Ki-67 
primary antibodies using standard methods. 
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